Hepatocellular Carcinoma (HCC)NCT07157085
AI Multitask Model for HCC Treatment
An observational study of Hepatocellular Carcinoma (HCC), run by Sun Yat-sen University at 1 site in China.
Trial summary
We will integrate multi-modal cardiac data via an AI multitask framework to develop and validate concurrent models for liver function, treatment prognosis, and microvascular invasion (MVI) prediction in hepatocellular carcinoma. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Hepatocellular Carcinoma (HCC)
- What is being tested?
- Comprehensive treatment
- How many people
- 7,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2008to 31 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with HCC received comprehensive therapies such as liver resection, ablation, TACE, HAIC, targeted therapy, immunotherapy and radiotherapy
Who may be able to join
- age 18-75 years;
- HCC diagnosed according to the European Association for the Study of the Liver/American Association for the Study of Liver Diseases criteria)
- Eastern Cooperative Oncology Group performance status < 2;
- Child-Pugh class A or B liver function;
Who cannot join
- HCC combined with other malignancies;
- missing image data during perioperative period;
- lost to follow-up > 12 months.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: AI-Driven Multitask Model for Guiding Treatment Decision-Making in Hepatocellular Carcinoma
We will integrate multi-modal cardiac data via an AI multitask framework to develop and validate concurrent models for liver function, treatment prognosis, and microvascular invasion (MVI) prediction in hepatocellular carcinoma. The resulting tool will be prospectively deployed to guide personalized surgical, TACE, and systemic therapy decisions.
- Conditions
- Hepatocellular Carcinoma (HCC)
- Being tested
- Comprehensive treatment
- Keywords
- HCC, artificial intelligence, multitask deep learning, clinical decision support
- Medical subject headings
- Carcinoma, Hepatocellular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Comprehensive treatmentOther
Comprehensive HCC therapies include liver resection, TACE, HAIC, targeted therapy, immunotherapy and radiotherapy
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
from diagnosis of HCC to death or last follow-up
Measured: 60 months
Secondary outcomes (1)
Progression-free survival
from diagnosis of HCC to disease progression or last follow-up
Measured: 60 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Sep 2025
- Study start1 Jan 2008
- Primary completion31 Dec 2023
- Study completion31 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatocellular Carcinoma (HCC)Studies of the same condition, open and under way.
- More trials run by Sun Yat-sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 7,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sun Yat-sen University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zhen-Wei Peng, Sun Yat-sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07157085
- Sponsor's protocol ID
- [2024]593
- Status last verified
- Aug 2025
- First submitted
- 28 Aug 2025
- Last updated
- 5 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- AI-Driven Multitask Model for Guiding Treatment Decision-Making in Hepatocellular Carcinoma
- ClinicalTrials.gov ID
- NCT07157085
- Acronym / sponsor ID
- [2024]593
- Conditions
- Hepatocellular Carcinoma (HCC)
- Keywords
- HCC, artificial intelligence, multitask deep learning, clinical decision support
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 7,000 participants (actual)
- Lead sponsor
- Sun Yat-sen UniversityUniversity, hospital or other
- Study start
- 1 Jan 2008 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 31 Dec 2023 (actual)
- First posted
- 5 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We will integrate multi-modal cardiac data via an AI multitask framework to develop and validate concurrent models for liver function, treatment prognosis, and microvascular invasion (MVI) prediction in hepatocellular carcinoma. The resulting tool will be prospectively deployed to guide personalized surgical, TACE, and systemic therapy decisions.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with HCC received comprehensive therapies such as liver resection, ablation, TACE, HAIC, targeted therapy, immunotherapy and radiotherapy
Key inclusion criteria (4 listed)
- age 18-75 years;
- HCC diagnosed according to the European Association for the Study of the Liver/American Association for the Study of Liver Diseases criteria)
- Eastern Cooperative Oncology Group performance status < 2;
- Child-Pugh class A or B liver function;
Key exclusion criteria (3 listed)
- HCC combined with other malignancies;
- missing image data during perioperative period;
- lost to follow-up > 12 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Comprehensive treatmentComprehensive HCC therapies include liver resection, TACE, HAIC, targeted therapy, immunotherapy and radiotherapy | Other | – |
Primary outcome
Overall Survival
Time frame: 60 months
from diagnosis of HCC to death or last follow-up
1 secondary outcome
Progression-free survival
Time frame: 60 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Hepatocellular Carcinoma (HCC)
RecruitingPhase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Solid Tumors
RecruitingPhase 2
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)
Not yet recruitingPhase 3
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Not yet recruitingObservational study
Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC)
Not yet recruitingPhase 2
An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC
Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hepatocellular Carcinoma (HCC), run by Sun Yat-sen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (time frame: 60 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2025.